Exscientia Aigns A Major Deal with Sanofi

Biotech Exscientia has signed an agreement with Sanofi to develop up to 15 new drug candidates in oncology and immunology using Exscientia’s artificial intelligence platform. As part of the deal, Sanofi will make an upfront payment of $ 100 million to Exscientia. Additional milestone payments can reach $ 5.2 billion.

At the end of a recent CSIS, the French authorities announced an unprecedented amount of credits (7 billion euros): 1.5 billion for university hospital research, 2 billion for investment in health via bpi France , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenses reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in laboratory turnover,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the actual benefit is sufficient.

 

Reviewer overview

Exscientia Aigns A Major Deal with Sanofi - /10

Summary

Biotech Exscientia has signed an agreement with Sanofi to develop up to 15 new drug candidates in oncology and immunology using Exscientia's artificial intelligence platform

0 Bad!